Klinger Shannon Thyme sold $174K of MRNA
Klinger Shannon Thyme (Chief Legal Officer) sold 3,471 shares of Moderna, Inc. (MRNA) at $50.00 ($0.17M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider ownership and may marginally influence sentiment, but the pre-arranged 10b5-1 structure reduces interpretability as a forward-looking negative signal.
Market read
A routine 10b5-1 open-market sale by a senior officer; no new company-specific catalyst is included.
What to watch
The article provides only the sale details; it does not state whether there were concurrent buys, option exercises, or broader insider activity around the same window.
Background
This is a SEC Form 4 insider transaction disclosure for Moderna, Inc., reported via EDGAR.
Ticker impact
Moderna insider Form 4 shows Chief Legal Officer Klinger Shannon Thyme sold 3,471 shares in an open-market transaction under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a Form 4 insider sale, explicitly pre-arranged under Rule 10b5-1, with no accompanying operational/regulatory/financial catalyst described.
Market effects
Minimal—single-company insider sale without new clinical, regulatory, or financial information.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with periods of elevated insider risk management; traders may still use it as a near-term sentiment check.
Key entities
- issuerModerna, Inc.
MRNA, subject of the Form 4 insider transaction disclosure.
- insiderKlinger Shannon Thyme
Chief Legal Officer who sold shares under a Rule 10b5-1 plan.
